ENYO Pharma Appoints Jeff George as Chairman to Support Next Phase of Growth and Phase 3 Readiness
Leadership transition reinforces ENYO’s strategic positioning following positive Phase 2 results with Vonafexor in Alport Syndrome
ENYO preparing to enter Phase 3 following planned End-of-Phase 2 meeting with health authorities in Q3 2026
ENYO Pharma (“ENYO”), a clinical-stage biotechnology company developing innovative therapies for kidney diseases, today announced the appointment of Jeff George as Non-Executive Chairman of its Board of Directors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260602303074/en/ Jeff George Chairman, ENYO Pharma
